Sinovac is a Beijing-based bio-pharmaceutical company developing the SARS-CoV-2 vaccine called CoronaVac, an inactivated virus particle vaccine.
On January 13, 2021 the Brazillian clinical trial results were announced and found the vaccine to have 50.4% efficacy, BARELY over the 50% needed for regulatory approval.